Alerts
Masks are Required

Wearing masks helps us keep each other safe. Masks are required in our facilities.

If you cannot wear a mask, contact your care team before you visit to discuss telehealth. Patients and visitors not wearing masks will not be permitted to enter.

Skip Navigation

KU Cancer Center at ASCO

More than 42,750 people from 138 countries attended this year’s American Society of Clinical Oncology (ASCO) annual meeting. Members of The University of Kansas Cancer Center discussed their key findings and presented dozens of abstracts.

June 11, 2020

More than 42,750 people from 138 countries attended this year’s American Society of Clinical Oncology (ASCO) annual meeting. Held virtually for the first time ever, the meeting featured 2,600 faculty and speakers and 5,300 abstracts delivering the latest news in cancer research. Members of The University of Kansas Cancer Center discussed their key findings and presented dozens of abstracts.

See all abstracts and presentations involving cancer center members and KU Medical Center researchers.

KU Cancer Center presentation highlights

The below list includes oral abstract sessions and other presentations led by KU Cancer Center researchers and clinicians. Cancer center members were involved in several important research discussions at ASCO, and this is not an exhaustive list.

It’s not what you say, it’s how you say it: New genetic testing delivery models

Presenter: Jennifer Klemp, PhD, MPH

Video of Dr. Klemp’s presentation is available to registered ASCO attendees.

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

Presenter: Priyanka Sharma, MD

PARP inhibitors(i) are effective in BRCA-mutation-associated metastatic breast cancer(MBC). However, there are no studies evaluating PARPi + platin chemotherapy in BRCA wild-type(wt) TNBC. Approximately 1/2 of BRCAwt TNBC demonstrate homologous recombination deficiency (HRD) resulting in a BRCA-like phenotype which might render them sensitive to PARPi. S1416 compared the efficacy of cisplatin plus PARPi veliparib (Vel) or placebo (P) in 3 groups of MBC: gBRCA+; BRCA-like; and non-BRCA-like.

View the entire abstract.

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

Presenter: Qamar Khan, MD

Ribociclib (R) + letrozole (L) is superior to L in metastatic breast cancer (BC). Preoperative endocrine prognostic index (PEPI) score 0 after neoadjuvant endocrine therapy (NET) is associated with low risk of relapse without chemotherapy in ER+ BC. On-therapy change in Ki-67 predicts adjuvant recurrence. FELINE is a biomarker-based multicenter randomized trial comparing changes in Ki-67 and PEPI between L+ Placebo (P) & L+R.

View the entire abstract.

Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.

Presenter: Anwaar Saeed, MD

Cabo targets multiple tyrosine kinases, including VEGFR, MET, and AXL, and has been reported to show immunomodulatory properties that may counteract tumor-induced immunosuppression, providing a rationale for combining it with PD-L1 inhibitors like durva. We conducted a phase Ib GI basket trial to evaluate the safety & efficacy of this regimen in advanced GE adenocarcinoma (GEA), colorectal cancer (CRC), & hepatocellular carcinoma (HCC).

View the entire abstract.

Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.

Presenter: Tara Lin, MD

CPX-351 (Vyxeos; daunorubicin [D] and cytarabine [C] liposome for injection) is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In a phase 3 study (NCT01696084) in patients (pts) aged 60-75 y with newly diagnosed high-risk/secondary AML, CPX-351 demonstrated significantly longer overall survival (OS) and higher rates of remission and hematopoietic cell transplant (HCT) vs conventional 7+3, with a comparable safety profile. To better understand the impact of treatment on outcomes in pts who did not undergo HCT, this exploratory analysis evaluated outcomes in the subgroup who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi) with CPX-351 vs 7+3 but did not undergo HCT.

View the entire abstract.

Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).

Presenter: Tara Lin, MD

CPX-351 (Vyxeos; daunorubicin and cytarabine liposome for injection) is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In a phase 3 study in patients (pts) aged 60-75 y with newly diagnosed high-risk/secondary AML who were fit for IC, CPX-351 significantly improved median survival versus 7+3 cytarabine/daunorubicin and had a comparable safety profile. However, it may not be appropriate to administer CPX-351 at the label dosage in pts unfit for IC. Venetoclax, a BCL-2 inhibitor, has clinical efficacy in combination with low-dose cytarabine in AML pts unfit for IC, and preclinical data suggest a rationale for combining CPX-351 and venetoclax. This study thus evaluates CPX-351 LIT in combination with venetoclax in AML pts unfit for IC.

View the entire abstract.

Explore more news, events and blog